Our results indicate than the Pro/Pro genotype is associated with a good response to anti-HER2 drugs (>90% tumor reduction): in the whole patient sample, 58.62% of good responders were of the Pro/Pro genotype versus only 20% for the remaining genotypes (p = 0.025, Table 3). The gene discussed is ERBB2; the disease is neoplasm.